Exeter, United Kingdom
SENISCA, founded in 2020, is a promising biotech spinout from the University of Exeter, specializing in the development of senotherapeutics—innovative solutions aimed at reversing cellular senescence. Using pioneering advances in molecular genetics, SENISCA seeks to address both diseases and aesthetic signs associated with aging.
The company's approach is centered on a patent-protected technique that rejuvenates old cells by tweaking gene expression. This hallmark innovation positions SENISCA at the forefront of biotechnology in the intersection of Biotechnology and Health Care industries.
Headquartered in the United Kingdom, SENISCA recently secured a £3.70M Seed Round investment on March 18, 2024. Key investors in this round included Apex Ventures, R42, Emerging Longevity Ventures, QantX, Trend Investment Group, and Lifespan Vision Ventures, highlighting strong confidence in its groundbreaking research and commercial potential.
